Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study (Q48881943)

16 February 2018

title

Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study (English)

1 reference

16 February 2018

relapsing-remitting multiple sclerosis

main subject

0 references

multiple sclerosis

0 references

patient

0 references

author

Bianca Weinstock-Guttman

2

object named as

B Weinstock-Guttman

1 reference

16 February 2018

author name string

R A Bermel

1

1 reference

16 February 2018

D Bourdette

3

1 reference

16 February 2018

P Foulds

4

1 reference

16 February 2018

X You

5

1 reference

16 February 2018

R A Rudick

6

1 reference

16 February 2018

publication date

18 February 2010

1 reference

16 February 2018

Multiple Sclerosis Journal

number of pages

9

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

16 February 2018

volume

16

1 reference

16 February 2018

issue

5

1 reference

16 February 2018

page(s)

588-596

1 reference

16 February 2018

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1352458509360549

Interferon-beta1a: a once-weekly immunomodulatory treatment for patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509360549

Getting specific: monoclonal antibodies in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509360549

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509360549

Disability progression in multiple sclerosis is slower than previously reported.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509360549

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509360549

Using the SF-36 measure to compare the health impact of multiple sclerosis and Parkinson's disease with normal population health profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509360549

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509360549

Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509360549

Association of fatigue and brain atrophy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509360549

Factors that predict health-related quality of life in patients with relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509360549

Eight-year follow-up study of brain atrophy in patients with MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509360549

The MOS 36-ltem Short-Form Health Survey (SF-36)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509360549

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509360549

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509360549

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509360549

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509360549

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509360549

21 January 2018

Identifiers

DOI

10.1177/1352458509360549

1 reference

16 February 2018

1 reference

16 February 2018